Last mentioned: Mar 21, 2026
Annual Results Announcement
Official report confirms a retreat in full-year net income compared to the previous fiscal year.
VBP Participation
Company participates in multi-province centralized procurement for intraocular lenses, securing volume at lower price points.
Aesthetics Expansion
Haohai launches new line of high-end dermal fillers to compete in the premium aesthetics market.
Shanghai Haohai Biological Technology Co., Ltd. has reported a decline in full-year income for the 2025 fiscal year, driven by margin compression in its core ophthalmology and orthopedic segments. The retreat highlights the ongoing challenges of China's volume-based procurement (VBP) policies and intensifying competition in the medical aesthetics market.
Shanghai Haohai Biological Technology Co., Ltd. has reported a retreat in its full-year net income, reflecting the intensifying impact of China's centralized procurement policies. The decline underscores the challenges facing domestic medtech leaders as they navigate margin compression in ophthalmology and heightened competition in the medical aesthetics market.